创新药企必贝特：自主研发管线迎来收获期

Core Viewpoint - Guangzhou Bibetter Pharmaceutical Co., Ltd. has initiated its initial public offering (IPO) on the Sci-Tech Innovation Board, with a subscription rate of 0.0477%, marking a significant step for the company and reflecting regulatory support for unprofitable tech enterprises [1] Group 1: Company Overview - Bibetter focuses on innovative drug development with a clinical value orientation, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders [1][2] - The company has established a competitive research and development pipeline, having received over 30 clinical approvals since its inception [2] Group 2: Key Products - The first approved product, BEBT-908, is a First-in-Class small molecule dual-target inhibitor designed for treating various hematological malignancies and solid tumors [2][3] - BEBT-908 has received "breakthrough therapy" designation for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) and is undergoing clinical trials for additional indications [3] Group 3: Financial Aspects - The total fundraising amount for the IPO is 1.6 billion yuan, which will be primarily allocated to new drug research and development, production facility construction, and working capital [4] - The company aims to leverage its core technology platform to accelerate clinical development and expand its product line to meet unmet clinical needs [4]